Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. George is active.

Publication


Featured researches published by S. George.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

Katherine A. Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R. Ball; Margarita Raygada; Angela H. Lai; Lorna Kelly; Jason L. Hornick; S. George; Michael P. LaQuaglia; Alberto S. Pappo; Jonathan Trent; Margaret von Mehren; Maureen J. O'Sullivan; Ronald R. de Krijger; Winand N. M. Dinjens; George D. Demetri; Cristina R. Antonescu; Jonathan A. Fletcher; Lee J. Helman; Constantine A. Stratakisc

Carney-Stratakis syndrome, an inherited condition predisposing affected individuals to gastrointestinal stromal tumor (GIST) and paraganglioma, is caused by germline mutations in succinate dehydrogenase (SDH) subunits B, C, or D, leading to dysfunction of complex II of the electron transport chain. We evaluated the role of defective cellular respiration in sporadic GIST lacking mutations in KIT or PDGFRA (WT). Thirty-four patients with WT GIST without a personal or family history of paraganglioma were tested for SDH germline mutations. WT GISTs lacking demonstrable SDH genetic inactivation were evaluated for SDHB expression by immunohistochemistry and Western blotting and for complex II activity. For comparison, SDHB expression was also determined in KIT mutant and neurofibromatosis-1–associated GIST, and complex II activity was also measured in SDH-deficient paraganglioma and KIT mutant GIST; 4 of 34 patients (12%) with WT GIST without a personal or family history of paraganglioma had germline mutations in SDHB or SDHC. WT GISTs lacking somatic mutations or deletions in SDH subunits had either complete loss of or substantial reduction in SDHB protein expression, whereas most KIT mutant GISTs had strong SDHB expression. Complex II activity was substantially decreased in WT GISTs. WT GISTs, particularly those in younger patients, have defects in SDH mitochondrial complex II, and in a subset of these patients, GIST seems to arise from germline-inactivating SDH mutations. Testing for germline mutations in SDH is recommended in patients with WT GIST. These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis.


Journal of Clinical Oncology | 2010

Cutaneous angiosarcoma of the head and neck.

P. K. Pandalai; Jason L. Hornick; Qian Wang; Jeffrey A. Morgan; S. George; Elizabeth H. Baldini; Phillip M. Devlin; Chandrajit P. Raut

10067 Background: Surgical management of cutaneous angiosarcoma (AS) of the head and neck (HN) in the absence of adjuvant therapy is associated with rapid recurrence and median survival of <30 mo. ...


Journal of Clinical Oncology | 2008

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial.

Andrew J. Wagner; Jeffrey A. Morgan; Rashmi Chugh; Lee S. Rosen; S. George; Michael S. Gordon; C. M. Devine; A. D. Van Den Abbeele; David Grayzel; George D. Demetri


Journal of Clinical Oncology | 2011

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

George D. Demetri; Michael C. Heinrich; Bartosz Chmielowski; Jeffrey A. Morgan; S. George; R. Bradley; R. K. Blackman; F. Teofilovici; Jonathan A. Fletcher; William D. Tap; M. von Mehren


Journal of Clinical Oncology | 2011

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

S. George; M. von Mehren; Michael C. Heinrich; Qian Wang; Christopher L. Corless; James E. Butrynski; Jeffrey A. Morgan; Andrew J. Wagner; Edwin Choy; William D. Tap; Judith Manola; Jeffrey T. Yap; A. D. Van Den Abbeele; Scott D. Solomon; Jonathan A. Fletcher; George D. Demetri


Journal of Clinical Oncology | 2008

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

Mary L. Keohan; Jeffrey A. Morgan; David R. D'Adamo; David C. Harmon; James E. Butrynski; Andrew J. Wagner; Gary K. Schwartz; Robert G. Maki; George D. Demetri; S. George


ASCO Meeting Abstracts | 2006

Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST

S. George; Paolo G. Casali; J. Blay; A. Le Cesne; A. R. Tyler; M. T. Quigley; Vanessa Tassell; Charles M. Baum; George D. Demetri


Journal of Clinical Oncology | 2005

Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy

Jayesh Desai; P. Dileo; Jeffrey A. Morgan; P. R. Larsen; Ming-Hui Chen; S. George; J. Jackson; Charles M. Baum; George D. Demetri


Journal of Clinical Oncology | 2008

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

S. George; J. Y. Blay; Paolo G. Casali; A. Le Cesne; Samuel E. DePrimo; Charles S. Harmon; C.N.J. Law; Vanessa Tassell; Charles M. Baum; George D. Demetri


ASCO Meeting Abstracts | 2007

Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST

S. George; J. Blay; Paolo G. Casali; A. Le Cesne; Jeffrey A. Morgan; J. Pokela; M. T. Quigley; Vanessa Tassell; Charles M. Baum; George D. Demetri

Collaboration


Dive into the S. George's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jason L. Hornick

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Jonathan A. Fletcher

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge